Navigation Links
Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
Date:5/7/2008

WASHINGTON, May 7 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented today at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound is an investigational once-daily medication, which is being evaluated for the treatment of the symptoms of Attention Deficit Hyperactivity Disorder (ADHD). The data demonstrated that INTUNIV showed significant efficacy in reducing ADHD symptoms for patients taking the medication when compared to patients taking placebo at all measured time points up to 24 hours postdose.

The U.S. Food and Drug Administration (FDA) issued an approvable letter on June 20, 2007, regarding INTUNIV. Shire is conducting additional clinical work which is designed to enhance the label. Upon approval, INTUNIV will be the first selective alpha-2A receptor agonist indicated for the treatment of ADHD that may provide an important treatment option for patients and physicians.

Summary of Analyses

The pooled analysis evaluated results from these patients on a weight adjusted mg/kg basis from two similarly designed, randomized, double-blind, forced-dose titration, multicenter phase III trials. The primary efficacy measure for both studies was change in the ADHD Rating Scale (ADHD-RS-IV) total score from baseline to endpoint. All patient groups treated with INTUNIV showed significantly greater improvement in ADHD-RS-IV total score from baseline to endpoint than the placebo group (P<.001). The ADHD-RS-IV is a standardized, validated test for assessing symptoms of ADHD and for assessing their response to treatment.

The analysis also studied duration of effect using the Conners' Parent Rating Scale-Revised Short Form (CPRS-R), which is a comprehensive scale that used observer and self-report ratings to help assess ADHD and evaluate behavioral issues in children and adolescents. The CPRS-R asses
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
2. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
3. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
4. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
5. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
6. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
7. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
8. SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
9. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
10. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
11. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... WASHINGTON , May 22, 2015  The ... certain diagnosed victims of mesothelioma get the best ... making certain individuals with this rare cancer caused ... the most up-to-date information related to treatment options ... information please call the Mesothelioma Victims Center anytime ...
(Date:5/22/2015)... Today, Rhodes Pharmaceuticals L.P. announced that Aptensio ... for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will ... The announcement comes just one month ... Food and Drug Administration (FDA). ... capsule with an onset of effect of 1 ...
(Date:5/21/2015)... DUBLIN , May 21, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/5x377m/north_american ) has announced the addition of ... by Type (Ankle Replacement, Digit Replacement, Elbow ... - Forecast to 2019" report to ... market for knee replacement was valued at ...
Breaking Medicine Technology:Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2
... in a physicians office practice, can be instrumental ... ailments; UTIs, diabetes, several cancers, metabolic disorders, cardiovascular ... for urinalysis tests is well in excess of ... For such a fundamental, extensive and economically significant ...
... large multi-site lab faced challenges with manual document ... were exacerbated by staff shortages and growing test ... was essential for accreditation compliance and also to ... manage documents. They therefore assessed a variety of ...
Cached Medicine Technology:Urinalysis Analyzers: Large Capabilities in Every Size Device 2Urinalysis Analyzers: Large Capabilities in Every Size Device 3Choosing Lab Quality Management Software 2Choosing Lab Quality Management Software 3Choosing Lab Quality Management Software 4
(Date:5/24/2015)... Pacific Prime has announced that they have launched the second ... of individual international health insurance. Titled: The Cost of Health Insurance ... health insurance in six top expat destinations, which are also popular ... Kong , Singapore , China , ... UK , Article 2 presents an in-depth look at ...
(Date:5/24/2015)... Scientists with Cardno ChemRisk, a scientific ... compliance issues that may have raised the risk of ... just posted an article on the research. Click ... found airborne asbestos levels well above OSHA safety guidelines ... 2011. , “Asbestos compliance sampling data associated with the ...
(Date:5/24/2015)... Medicx Media Solutions http://www.medicxmedia.com ... Jay Krihak as its head of programmatic strategy ... its expertise and leadership position in the data ... sectors. , Krihak is an experienced, award-winning agency ... led sales planning teams for mobile platform Jumptap. ...
(Date:5/23/2015)... 2015 Dr. David Benvenuti, an experienced plastic ... a new article to his website that takes ... Benvenuti explained in the fascinating blog, he has recently ... earlobes. , Known as “gauging,” the technique involves placing larger ... Benvenuti said will eventually stretch the holes out to incredible ...
(Date:5/23/2015)... 23, 2015 A live auction will be ... hospitals, surgery centers and other medical facilities around the United ... endoscopy, lab, radiology, surgery, anesthesia, exam and much more. ... and Thursday, May 28 starting at 9:00am CDT each day. ... N. 25th Avenue, Melrose Park, IL 60160. Anyone can ...
Breaking Medicine News(10 mins):Health News:Pacific Prime Releases 2nd Article of Cost of Health Insurance Report 2Health News:New Analysis Finds Too Many Employers Ignored OSHA Asbestos Guidelines, According to Surviving Mesothelioma 2Health News:Medicx Media Solutions Expands Executive Team 2Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2
... Amgen (Nasdaq: AMGN ) will present ... on Monday, May 18, 2009 at the InterContinental, Boston, ... and Chief Executive Officer Kevin Sharer will present. Live ... Internet and can be accessed from Amgen,s Web site, ...
... treatment prolonged survival in older women, study finds , ... with early-stage breast cancer do better after standard chemotherapy ... a new study finds. , "After three years, 85 ... and 68 percent of people who received capecitabine ...
... ("SCA") today announced that it will host an investor ... May 19, 2009, to discuss its 2009 first quarter ... ) Please go to SCA,s Intralinks website to obtain ... or contact Kathleen Vojta at 205-545-2693 or by e-mail ...
... Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: ... for disease indications with large markets, today announced its ... Selected Highlights, -------------------, ... 2009 and up to the date of this press,release, ...
... VIEW, Calif., May 13 MAP Pharmaceuticals, Inc. (Nasdaq: ... at the Deutsche Bank Securities 34th Annual Health ... (ET) in Boston, MA.A live webcast of the presentation will ... website at http://www.mappharma.com . A replay will also be ...
... Katherine Borden, at the Institute for Research in Immunology ... shown that a common anti-viral drug, ribavirin, can be ... the journal Blood (First Edition), the study ... gene in patients. This gene is dysregulated in 30 ...
Cached Medicine News:Health News:Chemotherapy Superior to New Drug for Early Breast Cancer 2Health News:Chemotherapy Superior to New Drug for Early Breast Cancer 3Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 2Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 3Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 4Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 5Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 6Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 7Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 8Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 9Health News:Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results 10Health News:Novel therapy may prove effective in treatment of 30 percent of cancers 2
Smooth, round edges allow for safe manipulation within the eye. 1.1mm wide gradually tapers to .50 mm wide. 45, 1.1mm wide, gradually tapers to .50mm wide....
Designed to lift corneal cap/flap during corneal lamellar surgery...
Pre-expanded for convenience; no need to pre-soak and fan. Lint-free PVAmaterial...
Angled 45, 9mm from end, Longer design from bend to tip allows for easier placement of viscoelastic to all meridians, Dome shape, extra smooth tip...
Medicine Products: